Multi-organ system and quality-of-life benefits sustained through three and a half years 86% response rate for the multi-component endpoint 89% of patients completed the three-and-a-half-year...
– Multi-organ system and quality-of-life benefits sustained through five years of treatment – 82% response rate for the multi-component endpoint – 95% of patients completed five years...
COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achondroplasia,...
Ascendis Pharma A/S (NASDAQ:ASND) reported first-quarter 2026 results highlighted by the U.S. FDA approval of its third TransCon product, YUVIWEL, and continued growth across its rare endocrine portfolio....
- Q1 2026 revenue of €197 million for YORVIPATH ®  and €44 million for SKYTROFA ® - More than 1,000 new patient enrollments for YORVIPATH in the U.S. in Q1 - As of May 1, more than...
Barchart Research What to Expect from ASND Earnings ASND Generated May 6, 2026 Current Price $235.90 EPS Estimate $$0.21 Consensus Rating Strong Buy Average Move 4.66% Ascendis Pharma's First Profitable...
COPENHAGEN, Denmark, May 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from a subgroup analysis showing that children with achondroplasia ≥5 years of age...
COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report first quarter 2026 financial results and provide a business update on Thursday,...
COPENHAGEN, Denmark, April 21, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has called all $575.0 million aggregate principal amount of its outstanding 2.25% Convertible...
COPENHAGEN, Denmark, April 20, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the commencement of trading of its ordinary shares on The Nasdaq Global Select Market (Nasdaq),...